Analytical Data
-
Gene name
DSE
- Application
-
Alternative Names
DSEPI; SART2; Squamous Cell Carcinoma Antigen Recognized By T Cells 2; Chondroitin-glucuronate 5-epimerase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UL01
-
Expression Region
Tyr23~Glu775
-
Molecular Weight
110kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DSE (Dipeptidyl Peptidase-4, or DPP-4) is a serine protease that has garnered significant attention in recent years due to its critical role in glucose metabolism and immune regulation. Initially identified for its involvement in the inactivation of incretin hormones, such as GLP-1, which are essential for insulin secretion, DSE has emerged as a pivotal target for therapeutic intervention in diabetes management. The increasing prevalence of type 2 diabetes has prompted extensive research into DSE and its inhibitors, leading to the development of DPP-4 inhibitors as a novel class of anti-diabetic medications. These inhibitors not only improve glycemic control but also exhibit potential cardiovascular and renal benefits. Furthermore, recent studies have expanded our understanding of DSE's functions beyond glucose homeostasis, revealing its implications in inflammatory responses and cancer biology. The ongoing exploration of DSE's structural biology, including its enzyme kinetics and interaction with various substrates, is crucial for designing more effective inhibitors and understanding its broader physiological roles. This research holds promise for innovative therapeutic strategies aimed at addressing not just diabetes, but also associated metabolic disorders, making DSE a focal point in contemporary biomedical research.
